Skip to main content

Table 1 Patient demographics and clinical characteristics pre- and post-matching

From: Comparative effectiveness of urate lowering with febuxostat versus allopurinol in gout: analyses from large U.S. managed care cohort

  Pre-matched Fully matched Treatment-naïve matched
  Total (N = 16,040) Febuxostat (N = 2,015) Allopurinol (N = 14,025) P value a Total (N = 3,864) Febuxostat (N = 1,932) Allopurinol (N = 1,932) P value a Total (N = 1,746) Febuxostat (N = 873) Allopurinol (N = 873) P value a
Age, mean (SD) 55.9 (12.0) 56.0 (12.3) 55.9 (12.0) 0.81 55.6 (12.2) 56.0 (12.3) 55.2 (12.2) 0.076 55.4 (12.3) 55.2 (12.0) 55.6 (12.7) 0.57
Quan-Charlson comorbidity score, mean (SD) 0.56 (1.12) 0.78 (1.35) 0.53 (1.07) <0.001 0.68 (1.23) 0.75 (1.30) 0.61 (1.16) <0.001 0.64 (1.16) 0.69 (1.22) 0.58 (1.10) 0.063
  n (%) n (%) n (%)   n (%) n (%) n (%) P value a n (%) n (%) n (%) P value a
Age             
  18-44 2,856 (17.8%) 388 (19.3%) 2,468 (17.6%) 0.07 742 (19.2%) 367 (19.0%) 375 (19.4%) 0.74 348 (19.9) 178 (20.4) 170 (19.7) 0.63
  45-64 9,402 (58.6%) 1,123 (55.7%) 8,279 (59.0%) 0.005 2,196 (56.8%) 1,086 (56.2%) 1,110 (57.5%) 0.44 974 (55.8) 506 (58.0) 468 (53.6) 0.07
  65-74 2,660 (16.6%) 356 (17.7%) 2,304 (16.4%) 0.16 661 (17.1%) 339 (17.6%) 322 (16.7%) 0.47 298 (17.1) 131 (15.0) 167 (19.1) 0.02
  75 and older 1,122 (7.0%) 148 (7.3%) 974 (6.9%) 0.51 265 (6.9%) 140 (7.3%) 125 (6.5%) 0.34 126 (7.2) 58 (6.6) 68 (7.8) 0.36
Gender             
  Male 13,607 (84.8%) 1,682 (83.5%) 11,925 (85.0%) 0.07 3,247 (84.0%) 1,610 (83.3%) 1,637 (84.7%) 0.24 1,457 (83.4) 740 (84.8) 717 (82.1) 0.14
  Female 2,433 (15.2%) 333 (16.5%) 2,100 (15.0%)   617 (16.0%) 322 (16.7%) 295 (15.3%)   289 (16.5) 133 (15.2) 156 (17.9) 0.14
Insurance type     0.04     0.33     <0.001
  Commercial 13,429 (83.7%) 1,656 (82.2%) 11,773 (83.9%)   3,203 (82.9%) 1,590 (82.3%) 1,613 (83.5%)   1,433 (82.1) 746 (85.4) 687  
Medicare Advantage 2,611 (16.3%) 359 (17.8%) 2,252 (16.1%)   661 (17.1%) 342 (17.7%) 319 (16.5%)   313 (17.9) 127 (14.5) 186  
Geographic location             
  Northeast 1,168 (7.3%) 137 (6.8%) 1,031 (7.4%) 0.37 280 (7.3%) 132 (6.8%) 148 (7.7%) 0.32 137 (7.8) 74 (8.5) 63 (7.2) 0.33
  Midwest 1,450 (9.0%) 143 (7.1%) 1,307 (9.3%) 0.001 273 (7.1%) 140 (7.3%) 133 (6.9%) 0.66 111 (6.4) 49 (5.6) 62 (7.1) 0.20
  South 11,020 (68.7%) 1,482 (73.6%) 9,538 (68.0%) <0.001 2,811 (72.8%) 1,415 (73.2%) 1,396 (72.3%) 0.49 1,256 (71.9) 640 (73.3) 616 (70.6) 0.20
  West 2,402 (15.0%) 253 (12.6%) 2,149 (15.3%) 0.001 500 (12.9%) 245 (12.7%) 255 (13.2%) 0.63 242 (13.9) 110 (12.6) 132 (15.1) 0.13
Allopurinol use 5,543 (34.6%) 748 (37.1%) 4,795 (34.2%) 0.010 1,306 (33.8%) 679 (35.1%) 627 (32.5%) 0.08     
Comorbidities             
Kidney failure 310 (1.9%) 77 (3.8%) 233 (1.7%) <0.001 126 (3.3%) 61 (3.2%) 65 (3.4%) 0.72 43 (2.5%) 23 (2.6%) 20 (2.3%) 0.64
Heart failure 772 (4.8%) 141 (7.0%) 631 (4.5%) <0.001 256 (6.6%) 126 (6.5%) 130 (6.7%) 0.80 106 (6.1%) 55 (6.3%) 51 (5.8%) 0.69
Peripheral arterial disease 200 (1.3%) 34 (1.7%) 166 (1.2%) 0.06 65 (1.7%) 30 (1.6%) 35 (1.8%) 0.53 24 (1.4%) 10 (1.1%) 14 (1.6%) 0.64
Osteoarthritis 2,686 (16.8%) 418 (20.7%) 2,268 (16.2%) <0.001 760 (19.7%) 388 (20.1%) 372 (19.3%) 0.52 325 (18.6%) 155 (17.7%) 170 (19.5% 0.36
Hypertension 9,844 (61.4%) 1,368 (67.9%) 8,476 (60.4%) <0.001 2,598 (67.2%) 1,297 (67.1%) 1,301 (67.3%) 0.89 1,145 (65.6%) 572 (65.5%) 573 (65.6%) 0.96
Hyperlipidemia 8,857 (55.2%) 1,161 (57.6%) 7,696 (54.9%) 0.021 2,221 (57.5%) 1,114 (57.7%) 1,107 (57.3%) 0.82 984 (56.4%) 489 (56.0%) 495 (56.7%) 0.77
  Mean (SD) Mean (SD) Mean (SD) P value Mean (SD) Mean (SD) Mean (SD) P value Mean (SD) Mean (SD) Mean (SD) P value
Baseline sUA 8.3 (2.0) 8.4 (2.2) 8.2 (2.0) 0.036 8.3 (2.1) 8.4 (2.2) 8.3 (2.0) 0.97 8.7 (1.8) 8.7 (2.0) 8.7 (1.7) 0.85
  1. *P value is for comparison of febuxostat and allopurinol. SD, standard deviation; sUA, serum urate.